9-position Substituted Patents (Class 514/180)
  • Patent number: 10174071
    Abstract: The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and/or preventing the signs and/or symptoms of disorders such as blepharitis, meibomian gland dysfunction or skin inflammation or a respiratory disease (e.g., asthma).
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: January 8, 2019
    Assignee: NICOX OPHTHALMICS, INC.
    Inventors: Thomas Cavanagh, Shikha P. Barman, Tian Hao, Thomas B. Leland, Ritesh V. Thekkedath
  • Patent number: 10117938
    Abstract: Disclosed are aqueous pharmaceutical compositions which provide sustained released delivery of corticosteroid compounds. The pharmaceutical composition comprises a soluble corticosteroid and at least one viscosity enhancing agent. Also provided are methods for using the pharmaceutical compositions in an epidural injection, intra-articular injection, or an intra-lesional injection.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: November 6, 2018
    Assignee: Semnur Pharmaceuticals, Inc.
    Inventor: Mahendra G. Shah
  • Patent number: 10016412
    Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) and Toll-like receptor agonist (TLR) through a linker and a multifunctional connector group or molecule.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: July 10, 2018
    Assignee: YALE UNIVERSITY
    Inventors: David Spiegel, Kelly Fitzgerald
  • Patent number: 9956177
    Abstract: A method of making a sustained release microsphere formulation, wherein the release rate of a bioactive ingredient is manipulated by controlling the crystallinity of said bioactive ingredient, includes the steps of combining the active ingredient and an encapsulating polymer in at least one solvent, or mixtures thereof, to form a dispersed phase and processing the dispersed phase without filtering, filtering the combined dispersed phase with a hydrophobic or a hydrophilic filter, or filtering the active ingredient and encapsulating polymer individually with a hydrophobic or hydrophilic filter before combining them to form the dispersed phase. The dispersed phase is then combined with a continuous phase to form the microsphere formulation.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 1, 2018
    Assignee: OAKWOOD LABORATORIES LLC
    Inventors: Tracy Richey, Bagavathikanun Chithambara Thanoo
  • Patent number: 9795655
    Abstract: Provided are methods for and compounds for modulating the complement system. In particular, compounds are provided that inhibit complement activation and compounds are provided that promote complement activation. The compounds are therapeutics by virtue of their effects on the complement system. Hence, the compounds that inhibit complement activation can be used for treatment of ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, inflammatory diseases and diseases with an inflammatory component, including Alzheimer's Disease and other neurodegenerative disorders.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: October 24, 2017
    Assignee: Catalyst Biosciences, Inc.
    Inventors: Edwin L. Madison, Jack Nguyen, Sandra Waugh Ruggles, Christopher Thanos
  • Patent number: 9192680
    Abstract: Novel compounds and pharmaceutical compositions are provided. In one aspect of the invention the compounds may be utilized in medical practice for treating pancreatic cancer.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: November 24, 2015
    Assignee: Aposense LTD.
    Inventors: Ilan Ziv, Hagit Grimberg
  • Patent number: 9134304
    Abstract: The invention provides methods and compositions useful for identifying polypeptides with desired characteristics in vitro.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: September 15, 2015
    Assignee: X-Body, Inc.
    Inventors: Richard W. Wagner, Alexander Litovchick, Yan Chen
  • Patent number: 9056067
    Abstract: A pharmaceutical composition is used to enhance immunity of the human body. The composition contains potent components of lanostane compounds. A method is devised to obtain an extract from metabolite, sclerotium, or fermentation product of Poria cocas (Schw) Wolf. The extract contains 5-60% of the lanostane compounds by weight of the extract. The extract is devoid of secolanostane capable of inhibiting immunity development.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: June 16, 2015
    Assignee: Sinphar Pharmaceutical Co., Ltd.
    Inventors: Hang-Chin Lin, Jerming Tseng, Hsiou-Yu Ding, Wen-Liang Chang, Chien-Lian Chao, Hsin-Wen Huang
  • Publication number: 20150147406
    Abstract: Biodegradable therapeutic agent incorporating microspheres formulated in a high viscosity carrier suitable for intraocular administration to treat an ocular condition.
    Type: Application
    Filed: June 6, 2014
    Publication date: May 28, 2015
    Inventors: Michael R. Robinson, Wendy M. Blanda, Hui Liu, Scott M. Whitcup, Patrick M. Hughes
  • Publication number: 20150148325
    Abstract: The invention provides extended release pro-liposomal, non-aqueous, pharmaceutical formulations of a hydrophobic active pharmaceutical ingredient (API) of low water solubility but readily dissolved in alcohols and methods for making same. The formulations can be administered by infiltration into an incision, or by injection.
    Type: Application
    Filed: May 9, 2013
    Publication date: May 28, 2015
    Inventors: Shimon Amselem, Michael Naveh
  • Publication number: 20150147320
    Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
    Type: Application
    Filed: December 16, 2014
    Publication date: May 28, 2015
    Inventors: SHEUE-FANG SHIH, PO-CHUN CHANG, YUN-LONG TSENG, LUKE S.S. GUO, KEELUNG HONG
  • Publication number: 20150140062
    Abstract: Intraocular implants may include a corticosteroid and a biodegradable polymer associated with the corticosteroid to facilitate the release of the corticosteroid into an eye for a period of time. In some embodiments, ocular conditions, such as diabetic macular edema can be treated through administration of an intraocular implant including a corticosteroid and a biodegradable polymer associated with the corticosteroid to the eye of a human at a frequency of about once every six months to about once a year.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 21, 2015
    Inventors: Jane-Guo Shiah, Rahul Bhagat, Wendy M. Blanda, Thierry Nivaggioli, Lin Peng, David Chou, David A. Weber
  • Publication number: 20150141350
    Abstract: A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer.
    Type: Application
    Filed: September 4, 2014
    Publication date: May 21, 2015
    Inventors: Rangaramanujam M. Kannan, Sujatha Kannan, Roberto Romero, Raghavendra S. Navath, Hui Dai, Anupa R. Menjoge
  • Publication number: 20150141389
    Abstract: The present disclosure relates to a semi-solid topical drug delivery formulation including a silicone-based excipient, at least one volatile solvent, at least one active configured to be topically delivered through a patient's skin for an intended therapeutic application, and at least one enhancer. The formulation may additionally optionally include at least one agent that provides occlusivity when the formulation is applied onto a patient's skin. The at least one active may be a healthcare and/or pharmaceutical active.
    Type: Application
    Filed: March 11, 2013
    Publication date: May 21, 2015
    Inventors: Hyder Aliyar, Robert Huber, Gary Loubert, Gerald Schalau
  • Publication number: 20150133415
    Abstract: Compositions, and methods of using such compositions, useful for placement, for example injection, into the interior of human or animal eyes are provided. Such compositions include a therapeutic component, such as one or more corticosteroids, a biocompatible polymeric component, and a solvent component. The composition is in a fluid form before placement in the interior of an eye, and becomes less fluid after the composition is placed in the eye to form an extended or delayed release drug delivery element or system. The drug delivery element is formed by the dissipation of the solvent from the composition when the composition is placed in the interior of an eye. One example of a composition includes triamcinolone acetonide as a therapeutic agent. A method of treating an ophthalmic condition, or otherwise improving or enhancing vision of a patient, comprises placing the fluid composition in the interior of the eye. The method may be practiced by injecting the fluid composition into the interior of the eye.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 14, 2015
    Inventor: Scott M. Whitcup
  • Publication number: 20150126483
    Abstract: The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic agent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and/or preventing the signs and/or symptoms of disorders such as blepharitis, meibomian gland dysfunction or skin inflammation or a respiratory disease (e.g., asthma).
    Type: Application
    Filed: May 6, 2013
    Publication date: May 7, 2015
    Inventors: Thomas Cavanagh, Shikha P. Barman, Tian Hao, Thomas B. Leland, Ritesh V. Thekkedath
  • Publication number: 20150126481
    Abstract: The present disclosure is drawn to an adhesive peel-forming formulation for dermal delivery of a drug, comprising a drug, a solvent vehicle, and a polymer peel-forming agent. The solvent vehicle can comprise a volatile solvent system comprising one or more volatile solvent, and a non-volatile solvent system comprising two or more non-volatile solvents. The non-volatile solvent system can have a solubility with respect to the drug that is within a window of operable solubility such that the drug is deliverable at therapeutically effective rates over a sustained period of time.
    Type: Application
    Filed: November 5, 2014
    Publication date: May 7, 2015
    Inventors: Jie Zhang, Kevin S. Warner, Michael A. Ashburn, Larry D. Rigby, Suyi Niu
  • Publication number: 20150125395
    Abstract: A method for changing a condition of an eyelid of a mammal excluding a human, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient.
    Type: Application
    Filed: June 18, 2013
    Publication date: May 7, 2015
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Hideki Miyake, Tomoko Oda
  • Publication number: 20150119827
    Abstract: Storage stable, topical lotion compositions for treating corticosteroid-responsive dermatoses are provided by the present invention which include a halobetasol material comprising halobetasol or its pharmaceutically acceptable salts, esters, and solvates; and a pharmaceutically acceptable carrier which includes: (a) one or more fatty alcohols and/or one or more alkoxylated fatty alcohols, (b) one or more polyol humectants, and (c) diisopropyl adipate. Storage stable, topical lotion compositions for treating corticosteroid-responsive dermatoses are provided by the present invention which include 0.05% halobetasol propionate; and a pharmaceutically acceptable carrier which includes: (a) one or more fatty alcohols and/or one or more alkoxylated fatty alcohols, (b) one or more polyol humectants, and (c) diisopropyl adipate.
    Type: Application
    Filed: January 9, 2015
    Publication date: April 30, 2015
    Inventors: Keith A. Johnson, Karl F. Popp
  • Patent number: 9012436
    Abstract: We describe lipid based pharmaceutical compositions adapted for oral delivery and optionally delivery in accordance with a circadian rhythm.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: April 21, 2015
    Assignee: Diurnal Limited
    Inventors: Hiep Huatan, Richard Ross
  • Patent number: 9012437
    Abstract: Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 ?g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 ?g/ml dexamethasone for at least about three weeks.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: April 21, 2015
    Assignee: Allergan, Inc.
    Inventors: Vernon G. Wong, Mae W. L. Hu
  • Publication number: 20150093440
    Abstract: A method of making aggregate particles suitable for a powder aerosol composition that includes forming a dispersion of nanoparticulate drug and/or excipient in a non-aqueous liquid, and spray-drying the dispersion to generate aggregate particles having a mass median aerodynamic diameter of less than or equal to about 100 microns, and particles generated by such method, and compositions of said particles.
    Type: Application
    Filed: October 13, 2011
    Publication date: April 2, 2015
    Applicant: GLAXO GROUP LIMITED
    Inventors: Michiel M. Van Oort, John N. Hong
  • Publication number: 20150087624
    Abstract: A nanoparticle aqueous dispersion in which nanoparticles are dispersed in water is produced through a method including a step of freeze-drying a frozen sample of a liquid mixture of a first solution and a second solution and a step of dispersing the freeze-dried sample in water. In this method, the liquid mixture contains an active ingredient and an ointment base, the first solution includes contains an organic solvent as its solvent, and the second solution contains water as its solvent. The method, which is arranged as such, can provide an aqueous composition containing nanoparticles dispersed therein and usable stably as an aqueous dispersion preparation.
    Type: Application
    Filed: April 23, 2013
    Publication date: March 26, 2015
    Inventors: Koichi Baba, Kohji Nishida, Noriyasu Hashida
  • Publication number: 20150087625
    Abstract: An injectable, flowable composition, kits that include the same, and methods of medical treatment of a mammal (e.g., human) that include the administration of the same are provided.
    Type: Application
    Filed: December 5, 2014
    Publication date: March 26, 2015
    Inventor: Jeff Missling
  • Patent number: 8974831
    Abstract: Carrier particles in which at least 60% of the surface is coated with magnesium stearate are useful for preparing dry powder formulations for inhalation.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: March 10, 2015
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Rossella Musa, Daniela Cocconi, Alain Chamayou, Laurence Galet
  • Publication number: 20150065474
    Abstract: Effective treatments of acute pain for extended periods of time are provided. Through the administration of an effective amount of dexamethasone at or near a target site, one can relieve pain cause by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least twenty-five days. In some embodiments, the relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.
    Type: Application
    Filed: October 30, 2014
    Publication date: March 5, 2015
    Inventors: John M. Zanella, Vanja M. King, Christopher M. Hobot, Stephen M. Cox, William F. McKay, Kathy L. Remsen
  • Patent number: 8962028
    Abstract: Storage stable, topical lotion compositions for treating corticosteroid-responsive dermatoses are provided by the present invention which include a halobetasol material comprising halobetasol or its pharmaceutically acceptable salts, esters, and solvates; and a pharmaceutically acceptable carrier which includes: (a) one or more fatty alcohols and/or one or more alkoxylated fatty alcohols, (b) one or more polyol humectants, and (c) diisopropyl adipate. Storage stable, topical lotion compositions for treating corticosteroid-responsive dermatoses are provided by the present invention which include 0.05% halobetasol propionate; and a pharmaceutically acceptable carrier which includes: (a) one or more fatty alcohols and/or one or more alkoxylated fatty alcohols, (b) one or more polyol humectants, and (c) diisopropyl adipate.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: February 24, 2015
    Assignee: MiCal Pharmaceuticals LLC—H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limited Liability Company
    Inventors: Keith A. Johnson, Karl F. Popp
  • Publication number: 20150051181
    Abstract: The present invention relates to a novel process for the production of nanoparticles laden with active compounds and to the use thereof as medicaments. The process for the production of nanoparticles comprises the steps (a) dissolution of at least one active compound and at least one polymer in an organic solvent, (b) mixing of the solution prepared in step (a) with an aqueous phase, (c) evaporation of the organic solvent, (d) purification of the nanoparticles laden with active compound obtained in step (c) by means of dialysis against aqueous dialysis solution comprising the same active compound.
    Type: Application
    Filed: February 11, 2013
    Publication date: February 19, 2015
    Applicant: Merck Patent GmbH
    Inventors: Markus Weigandt, Senta Voss, Tobias Miller, Achim Goepferich
  • Publication number: 20150044271
    Abstract: The present invention provides for pharmaceutical preparations, devices, systems and methods for the treatment of otic diseases and conditions. In various embodiments, the preparations, devices, systems and methods enable sustained drug release for the treatment or prevention of hearing loss, infections, and other pathological conditions of cochlea and inner ear.
    Type: Application
    Filed: February 27, 2013
    Publication date: February 12, 2015
    Applicant: O-RAY PHARMA, INC.
    Inventors: William H. Slattery, Thomas Smith, Erik Pierstorff, Marc M. Baum
  • Publication number: 20150038439
    Abstract: A process for producing a pharmaceutical suspension that comprises an active pharmaceutical ingredient (“API”) having low solubility, the process comprises: (a) preparing a first solution comprising a carboxy-containing vinyl polymer and a solvent; and (b) adding a compound of the API to said first solution under conditions of high-shear mixing for a time from about 5 minutes to about 5 hours, said compound being soluble in said solvent, thereby producing a suspension of particles of said API in a composition comprising said carboxy-containing vinyl polymer; wherein a concentration of said API in said suspension is higher than a solubility of said API in said solvent. The present invention also provides a suspension produced by such process.
    Type: Application
    Filed: October 21, 2014
    Publication date: February 5, 2015
    Inventors: Steven K. MacLeod, Daniel J. Stein, James Donald Hayes, Donald L. Herber
  • Publication number: 20150038473
    Abstract: Disclosed are stable compositions comprising povidone-iodine and a steroid, and methods of making and using such compositions. Also disclosed herein are stable compositions comprising povidone-iodine and an NSAID, and methods of making and using such compositions.
    Type: Application
    Filed: May 11, 2012
    Publication date: February 5, 2015
    Applicant: FORESIGHT BIOTHERAPEUTICS, INC.
    Inventors: Jason Stein, Michael Weiser, Joseph A. Capriotti, Bo Liang, C. Michael Samson
  • Publication number: 20150024034
    Abstract: The embodiments herein provide a nano-carrier system for delivering a long-acting injectable drug of dexamethasone and a method of synthesising the same. The dexamethasone entrapped nanoparticles are prepared using a lipid/phospholipid core which is coated by a polymer. The lipid and phospholipid are dissolved in organic solvent. This solution is transferred into an aqueous phase consisting of distilled water or a buffer. A solution of polymer is added drop wise. The drug entrapped nanoparticle formation is achieved by diffusion of the organic solvent within the aqueous solvent to obtain the nanoparticles. The drug gets entrapped within the nanoparticles via the anti-solvency effect of the aqueous matrix. The resulting drug nanocarriers are capable of releasing the drug in a slow rate upon injection. The synthesized drug carrying nanoparticles are cryopreserved stored for future administration. For better storage, the nanodispersion is dried to form a powder.
    Type: Application
    Filed: July 21, 2014
    Publication date: January 22, 2015
    Applicant: Kimia Zist Parsian Co
    Inventor: Mehrdad Hamidi
  • Publication number: 20150025051
    Abstract: The present invention is drawn to adhesive solidifying formulations for treating skin disorders, such as dermatitis or psoriasis. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least one volatile solvent, and a non-volatile solvent system including at least one non-volatile solvent, wherein the non-volatile solvent system is capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.
    Type: Application
    Filed: June 2, 2014
    Publication date: January 22, 2015
    Applicant: Nuvo Research Inc.
    Inventors: Jie Zhang, Kevin S. Warner, Sanjay Sharma
  • Publication number: 20150025020
    Abstract: The present invention relates to a self-preserved oil dispersion. Especially, the present invention relates to a self-preserved oil dispersion including a dispersed oil phase, an aqueous phase and at least one surfactant, wherein said oil dispersion comprises boric acid in an amount ranging from 0.005% to 0.075% in weight of the total weight of the oil dispersion, said amount of boric acid being a preservative effective amount so that the oil dispersion has a preservative activity.
    Type: Application
    Filed: February 22, 2013
    Publication date: January 22, 2015
    Inventors: Jean-Sébastien Garrigue, Frédéric Lallemand, Betty Philips
  • Publication number: 20150017103
    Abstract: The present invention relates to a waterless composition and foam as a vehicle in which an active pharmaceutical or cosmetic agent, when added is stable or stabilized by or its destabilization is impeded by the presence of a modulating agent. The pharmaceutical or cosmetic composition and foam, includes: a waterless solvent, a modulating agent and one or more active pharmaceutical or cosmetic agents. The present invention also relates to a method of treatment administering the waterless composition and foam.
    Type: Application
    Filed: October 3, 2013
    Publication date: January 15, 2015
    Applicant: Foamix Ltd.
    Inventors: Dov Tamarkin, Meir Eini, Doron Friedman, Tal Berman, David Schuz
  • Publication number: 20150011520
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.
    Type: Application
    Filed: February 8, 2013
    Publication date: January 8, 2015
    Inventors: Keelung Hong, Luke S.S. Guo, Sheue-Fang Shih, Po-Chun Chang, Chih-Chiang Tsai, Hong-Hul Lin, Yun-Long Tseng
  • Publication number: 20150011521
    Abstract: A method of controlled in vivo drug delivery is provided. A porous silicon matrix having pores sized and configured to admit to trap and then release a predetermined molecular complex with a predetermined dose-time profile is selected. The matrix contains the predetermined molecular complex so that the predetermined molecular complex is disposed within the pores of the porous silicon matrix. The matrix is introduced into a human body. The drug releases according the dose-time profile. The introduction can be via transdermal introduction, intramuscular injection, intravenous introduction, surgical implantation, inhalation, and oral ingestion.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 8, 2015
    Inventors: Michael J. Sailor, Guarav Abbi, Boycee E. Collins, Keiki-Pua S. Dancil
  • Patent number: 8927529
    Abstract: A method for the treatment of back pain by injection of an injectable flowable composition in the epidural space, wherein the composition is composed of microparticles of dexamethasone acetate and a polymer, are disclosed.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: January 6, 2015
    Assignee: SpineThera
    Inventor: Jeff Missling
  • Publication number: 20150004216
    Abstract: A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 1, 2015
    Inventor: Robert Steven Davidson
  • Patent number: 8920841
    Abstract: A polymer system useful for in vivo delivery of a therapeutic agent is provided. The polymer system comprises a biocompatible biodegradable polymeric backbone that is capable of a reversible stimuli-induced transition from liquid to gel.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: December 30, 2014
    Inventors: Heather Sheardown, Scott Fitzpatrick, M.A. Jafar Mazumder
  • Publication number: 20140377168
    Abstract: Pharmaceutical gels and methods for delivering a therapeutic agent to a target tissue site beneath the skin of a patient are provided, the gel being capable of adhering to the target tissue site and comprising one or more biodegradable depots containing an effective amount of the therapeutic agent. In various embodiments, the gel is sprayable and hardens after contacting the target tissue site.
    Type: Application
    Filed: September 5, 2014
    Publication date: December 25, 2014
    Inventors: John M. Zanella, William F. McKay
  • Publication number: 20140377332
    Abstract: Nano-constructs comprising nanoshells and methods of using the nano-constructs for treating or ameliorating a medical condition are provided.
    Type: Application
    Filed: November 21, 2013
    Publication date: December 25, 2014
    Inventors: Florian N. Ludwig, Stephen D. Pacetti, Syed F.A. Hossainy, Dariush Davalian
  • Publication number: 20140370072
    Abstract: Provided herein is a prohealing piezoelectric coating and the method of making and using the same.
    Type: Application
    Filed: September 3, 2014
    Publication date: December 18, 2014
    Inventors: Syed Faiyaz Ahmed Hossainy, Mikael Trollsas, Lothar Walter Kleiner
  • Publication number: 20140370097
    Abstract: The present invention provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time. The methods and compositions according to the invention are useful as therapeutic tools to prevent, reverse, and/or reduce the symptoms of allergic and/or inflammatory conditions in a mammalian patient. The invention also provides methods and compositions, which may be manipulated and fine-tuned to fit the condition(s) to be treated while producing fewer side effects.
    Type: Application
    Filed: June 20, 2014
    Publication date: December 18, 2014
    Inventors: Adrian Ashley, Paul Lamb, Donald MacDonald, John Miller, Martin J. Oliver, Mathew Pollard
  • Publication number: 20140364404
    Abstract: The present invention relates to articles and methods of treating vascular conditions with a thixotropic, turbid, bioactive agent-containing gel material capable of being essentially removed from an implantation site upon re-establishment of fluid flow at the implantation site.
    Type: Application
    Filed: August 22, 2014
    Publication date: December 11, 2014
    Inventors: Robert L. Cleek, Paul D. Drumheller, Theresa A. Holland
  • Publication number: 20140364836
    Abstract: The present invention provides compositions containing (i) a pharmaceutically active agent selected from a group consisting of an arylcycloalkyamine of a derivative, analogue or pharmaceutically active salt thereof, and (ii) a biocompatible polymer or a combination of biocompatible polymers. The compositions or medicaments containing these compositions may be used for the prevention and/or treatment of inner ear diseases, e.g. tinnitus.
    Type: Application
    Filed: June 27, 2014
    Publication date: December 11, 2014
    Inventor: Thomas MEYER
  • Publication number: 20140363498
    Abstract: Some aspects of this disclosure relate to a method of treating an ophthalmic disease affecting an eye of a patient comprising forming a covalently-crosslinked hydrogel in situ at a peri-ocular, intra-ocular, or intra-vitreal site for controlled release of a therapeutic agent.
    Type: Application
    Filed: August 27, 2014
    Publication date: December 11, 2014
    Inventors: Amarpreet S. Sawhney, William H. Ransone, II
  • Patent number: 8906893
    Abstract: The present invention relates to substances, to electroluminescent device comprising these substances, and to the use thereof.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: December 9, 2014
    Assignee: Merck Patent GmbH
    Inventors: Rémi Manouk Anémian, Aurélie Ludemann, Thomas Eberle, Sigurd Hoeger, Eva Maria Reis, Vanessa Bobbe
  • Publication number: 20140357609
    Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.
    Type: Application
    Filed: August 19, 2014
    Publication date: December 4, 2014
    Inventors: Jeffrey L. Edelman, Kelly M. Harrison
  • Publication number: 20140356437
    Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.
    Type: Application
    Filed: August 18, 2014
    Publication date: December 4, 2014
    Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran